Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric pharmacokinetics and HPA-axis safety study of Duobrii lotion in plaque psoriasis
2019-002406-43Phase 2Active
- Sponsor
- Bausch Health
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of halobetasol propionate + tazarotene in plaque psoriasis, sponsored by Bausch Health. Primary endpoints: Safety of IDP-118 lotion administered topically once daily, Systemic absorption and pharmacokinetics and 1 more. Started Mar 2020; status: active.
02
Drugs
halobetasol propionate + tazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2019-002406-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002406-43.